The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.
Those showing a minimal response or no response should be taken off it - with all drug costs refunded by the manufacturer, Janssen-Cilag.
A Shelford Group trust is seeking further financial support from the Department of Health and Social Care after forecasting a deficit of almost £100m.
HSJ’s expert briefing on NHS finances, savings and efforts to get the health service back in the black.
The fortnightly newsletter that unpacks system leaders’ priorities for digital technology and the impact they are having on delivering health services. Contact Ben Heather in confidence here.
No comments yet